Articles tagged with Vaccine Development
Researchers at the University of Toronto have discovered a novel ionizable lipid nanoparticle that enables efficient muscle-focused mRNA delivery while minimizing off-target effects. The study demonstrates potent cellular immune responses and potential as a viable candidate for cancer vaccine development.
Researchers have identified a sequence within therapeutic mRNAs that causes unintended immune responses and found a way to correct these errors. By designing 'slip-resistant' mRNAs, the team aims to produce future mRNA vaccines with improved safety and efficacy.
Researchers at Osaka Metropolitan University have successfully developed a novel pneumococcal vaccine that demonstrates efficacy in suppressing pneumococcal pneumonia in macaques. The vaccine's design combines proprietary mucosal vaccine technology with pneumococcal surface proteins to cover a wide range of serotypes.
Researchers developed GraphNovo, a program that provides accurate understanding of peptide sequences in cells, improving immunotherapy for unique cases. The AI model enhances de novo peptide sequencing accuracy, filling gaps with precise mass data.
Researchers have successfully mapped the entire HLA class II landscape, predicting how pathogens are displayed on cell surfaces. The mapping reveals that multiple HLA variants play essential roles in autoimmune disorders and organ rejection, highlighting their potential for developing immunotherapy treatments.
A team of researchers developed a vaccine that stimulates regulatory T cells to suppress harmful immune cells, prolonging allograft survival in mice. This discovery identifies an analogous pathway in humans, suggesting potential treatment for autoimmune disorders and organ transplant patients.
A study of over 2,300 patients found that HIV-1 neutralizing antibody response decreases over time but highly potent broadly neutralizing antibodies remain detectable. This finding suggests a possible permanent vaccine response and is an important step toward developing an effective HIV-1 vaccine.
Researchers found that antibodies targeting the N-terminal domain have a lower ability to protect against delta variants compared to those targeting the receptor-binding domain. The study provides new insights into vaccine development, highlighting the importance of understanding antibody responses.
Bio-TCV, a typhoid conjugate vaccine developed by IVI and Bio Farma, has been licensed in Indonesia following marketing approval from BPOM. The vaccine is expected to provide protection against typhoid fever as early as 9 months of age.
The UK has launched four new research hubs to address challenges of vaccine manufacturing and delivery in developing countries. The hubs will use lessons from the global COVID-19 rollout to improve processes, with funding from £33 million UK aid and £1.5 million EPSRC co-funding.
A team of University of Maryland researchers developed a nasal spray vaccine that delivers the SARS-CoV-2 spike protein into cells of the airway, triggering an immune response that significantly reduced infection and spread of COVID-19. The technology can be adapted to induce immunity to other respiratory illnesses.
Researchers have discovered highly effective antibodies against P. aeruginosa that can block its type III secretion system and are effective against highly resistant bacteria. These 'pathoblockers' offer a potential therapeutic approach for treating acute and chronic infections with multi-resistant pathogens.
Novel vaccine candidates using Computationally Optimized Broadly Reactive Antigens (COBRAs) protect against multiple influenza B strains, including those from different lineages. These vaccines show long-lasting protection, potentially reducing the need for yearly updates.
Researchers used AI to identify 2 promising antigens as candidates for a gonorrhea vaccine, which accurately predicted reduction of bacterial populations. The antigens were tested in lab and animal models, showing efficacy in killing bacteria and decreasing bacterial burden.
Researchers discovered a malaria protein, PfAP2-P, that plays a key regulatory role in immune evasion and parasite development. This protein acts as an activator of proteins required for the parasite to exit infected red blood cells and invade new ones.
The Precision Vaccines Program at Boston Children's Hospital has been awarded a $9 million NIH contract to develop a small molecule adjuvant to enhance the effectiveness of flu vaccines. The collaboration with Inimmune aims to increase the body's immune response to vaccines and protect vulnerable populations.
Engineers developed a nanoparticle vaccine targeting S100A9, a protein that attracts cancer cells to the lungs. The vaccine significantly reduced lung tumor growth and improved survival rates in mice with metastatic breast cancer after surgery.
Researchers at Duke University Medical Center have developed a single nanoparticle vaccine that protects against SARS-CoV-1 and MERS coronaviruses in addition to SARS-CoV-2.
A Singaporean study found that unvaccinated COVID-19 survivors are at a heightened risk of heart complications almost a year after recovery. The study revealed a 56% higher risk of developing new heart complications among unvaccinated survivors compared to uninfected individuals.
A new study reveals that immunity to SARS-CoV-2 variants depends on previous exposure and vaccination history. The research found significant differences in immune responses to various variants, highlighting the need for personalized vaccine approaches.
Researchers at Tulane University discovered that prior exposure to Cytomegalovirus (CMV) significantly reduces the risk of birth defects and miscarriage during pregnancy. The study found that pre-existing immunity effectively limits transmission and protects against associated birth defects.
A new vaccine developed by USC researchers has shown promising results in protecting against deadly superbugs, including MRSA and Acinetobacter baumannii. The experimental shot activates immune cells to provide rapid protection against eight different bacteria and fungi species.
Researchers from the University of Pittsburgh and NIH Vaccine Research Center developed an animal model that more closely mimics human infection symptoms than any existing model. This model allows for rapid testing and deployment of new vaccine candidates in a crisis scenario, potentially saving lives against bird flu.
Researchers identified two SARS-CoV-2 protein mutations linked to severe COVID-19 symptoms and increased inflammation. The mutations, known as KR, were found in patients with higher viral loads and more severe symptoms.
A new vaccine candidate has shown protection against a range of coronaviruses, including current and future variants, by targeting the critical regions of the virus that it needs to complete its life cycle. The vaccine technology, developed at the University of Cambridge, aims to provide broad-based protection against emerging viruses.
Researchers at Cleveland Clinic have developed a potential vaccine candidate against Dabie Bandavirus using nanoparticles, which can deliver antigens at a lower dose with fewer side effects. The vaccine has shown promise in pre-clinical studies and could provide protection to adults over 50, who are most vulnerable to the virus.
A new experimental mRNA vaccine provides protection in preclinical animal models against infection from Borrelia burgdorferi, the bacteria that causes Lyme disease. The vaccine prevents the development of Lyme disease and may represent a powerful tool in reducing Lyme disease cases.
A Phase 1 trial of a preventive HIV vaccine candidate has begun enrollment in the US and South Africa. The vaccine, VIR-1388, aims to instruct immune cells to recognize and respond to HIV.
A new study published in Virology Journal confirms 25 different types of HPV prevalent in Nigeria, highlighting the need for region-specific vaccines. The discovery underscores the limitations of existing vaccines like Gardasil-9, which only protects against nine cancer-causing types.
The University of Colorado Anschutz Medical Campus has received a $54 million grant from the National Institutes of Health to advance clinical and translational science. The grant will enable the Colorado Clinical and Translational Sciences Institute (CCTSI) to translate discoveries into better health and patient care across the state.
Researchers have developed a new vaccination method that induces the production of antibodies in mucus, which can disable viruses. This approach has shown promising results in monkeys, suggesting that oral vaccines against SARS-CoV-2 may be more effective and popular than traditional subcutaneous vaccinations.
A recent study has shown that pneumococcal conjugate vaccines have significantly reduced the rate of invasive pneumococcal infection among children with sickle cell disease. The overall rate of IPD decreased by 87% in children under 4 years old, and by 80% in those aged 5 to 9.
The Mount Sinai Hospital received a $13 million NIH grant to create vaccines that can protect against various types of coronaviruses. The project aims to develop variant-proof, universal vaccines that offer broad protection against existing and future SARS-CoV-2 variants, pandemic, zoonotic, and seasonal coronaviruses.
Researchers at Pritzker Molecular Engineering have developed an 'inverse vaccine' that can eliminate autoimmune reactions associated with multiple sclerosis, type 1 diabetes, and rheumatoid arthritis. The vaccine works by removing the immune system's memory of a molecule, allowing it to tolerate healthy tissues.
A large study found that people with an evening chronotype were more likely to engage in unhealthy lifestyle behaviors such as smoking, poor sleep, and physical inactivity. These individuals had a 72% higher risk of developing diabetes compared to those with a morning chronotype.
The new approach boosts immunity by engineering nanoparticles and antigens to stimulate a stronger immune response. The vaccine induces a strong immune response when delivered intranasally, potentially leading to longer-lasting immunity and reduced costs.
A new study by University of Missouri biochemist Steven Van Doren reveals the fusion peptide's crucial role in virus attachment and cell penetration. This research could inform the development of more effective vaccines capable of fighting all types of coronavirus infections.
Scientists have established the effectiveness of vaccines against leishmaniasis in animal studies, revealing specific molecular-level changes in host cells. The vaccines, created using mutated parasites, prompt distinct immune responses in hosts, offering new insights into their mechanisms and potential applications.
Researchers at the University of Montana are developing vaccines to prevent fentanyl and heroin drug overdoses. The first vaccine will target heroin, followed by a fentanyl vaccine in Phase I clinical trials. The vaccines aim to elicit antibodies against target opioids while sparing critical medications used in opioid addiction treatment.
A new AI-powered triage platform uses machine learning and metabolomics data to predict patient disease severity and length of hospitalization during a viral outbreak. The platform integrates routine clinical data, patient comorbidity information, and untargeted plasma metabolomics data to drive its predictions.
A new essay highlights how news stories about healthcare workers during COVID-19 often left out crucial socioeconomic and environmental contexts, which can impact consumer thoughts and responses. By introducing a public health framework, experts aim to broaden storytelling and reframed scientific information dissemination.
A new study finds SARS-CoV-2 infection significantly associated with development of high blood pressure in hospitalized adults. Persistent high blood pressure was more common in people with COVID-19 than influenza, highlighting potential long-term cardiovascular risk.
Researchers from the University of Kansas have created a powerful dataset to facilitate drug development against gram-negative bacteria. The dataset reveals over 270,000 previously unidentified outer-membrane proteins with potential as vaccine targets.
Researchers found that vaccines against tetanus, diphtheria, and shingles, as well as pneumococcus, may reduce the risk of developing Alzheimer’s disease by 25-30% in adults over 65. Vaccination is hypothesized to change how the immune system responds to toxic proteins contributing to Alzheimer’s disease.
A new machine-learning method, BigMHC, can accurately predict cancer-related protein fragments that may trigger an immune system response. By leveraging massive data through transfer learning, BigMHC enables scientists to develop personalized immunotherapies and vaccines by identifying the most likely to provoke an immune response.
A new Northwestern Medicine study measures resilience in biomedical scientists during COVID-19, revealing that resiliency did not guarantee career advancement. The study found that women scientists faced greater household responsibilities and social pressure to advance their careers, leading to significant career setbacks.
QUT researchers have created a booster vaccine using implant technology to protect wild koalas from Chlamydia disease. The new device allows for in-the-field vaccination without recapturing the animals, reducing human interference and increasing vaccination efficiency.
A University of Ottawa-led research team has made significant progress in understanding XLP-2, a genetic disorder that affects the immune system. The study reveals two underlying mechanisms: poor expression of Interleukin-6 and compromised T cell survival, which lead to immunodeficiency in patients.
The Access to Advanced Health Institute has received an $18 million award from the NIH to develop a temperature-stable, single-dose chikungunya RNA vaccine candidate. The vaccine uses innovative RNA platform technology to protect against the virus, which causes debilitating joint and muscle pain in endemic areas.
Biologists argue that building on genomic sequencing momentum is critical in society's response to future pandemics. The technology improved during the COVID-19 pandemic, but gaps remain in global infrastructure and data sharing.
Researchers discovered a protective immune feature lacking in people chronically infected with intestinal worms, leading to potential human vaccines and treatments. The study used animal models and found that blocking the T follicular helper response impaired worm clearance and promoted chronic infection.
A novel Raman technique called thermostable-Raman-interaction-profiling (TRIP) allows for label-free and highly reproducible Raman spectroscopy measurements, breaking a 50-year-old challenge. The TRIP method enables the detection of protein-ligand interactions in real-time, potentially shortening drug and vaccine testing timelines.
Scientists at the University of Pittsburgh Center for Vaccine Research have identified a protein responsible for lethal liver disease in mice infected with Rift Valley fever virus. Removing this protein, Lrp1, from the liver prevented viral replication and extended mouse lifespan.
Researchers developed a novel vaccine against SARS-CoV-2 by selecting antigen variants with low binding affinity, resulting in higher neutralizing antibody concentrations. This design strategy may also improve vaccine efficacy for other coronaviruses and herpes viruses.
Researchers developed a bioinformatic tool that selects parts of proteins to elicit strong immune responses. This approach, grounded in immunological theory, was four times more efficient than current methods, suggesting better vaccine protection against diseases.
Researchers have developed a computational tool to compare large datasets and predict immune responses to disease, potentially leading to better vaccines. The new algorithm, designed by La Jolla Institute for Immunology scientists, uses machine learning to identify underlying patterns in immune system data.
A study led by UCSF researchers discovered that people who remain asymptomatic after contracting COVID-19 often carry a specific gene variation that helps their immune system recognize the virus. This mutation, HLA-B*15:01, is common among asymptomatic individuals and can also help those with symptoms to recover more quickly.
CEPI and HMRI collaborate to leverage AI technology for faster vaccine development. The partnership aims to identify epitopes that stimulate the immune system, enabling swift clinical testing.
A survey of 2,000 German adults found that people with higher levels of empathy and cosmopolitanism are more likely to prioritize sharing vaccine supplies internationally. The study suggests that there is substantial public support for international vaccine solidarity when infection rates are at a modest level and falling.
Researchers at MIT are developing a continuous mRNA manufacturing platform to improve vaccine development and production. The pilot-scale system aims to reduce costs, increase efficiency, and facilitate collaboration in the biopharmaceutical industry.